Abstract
Mitoxantrone (MTO) is an anthraquinone antitumor drug with potent therapeutic benefits. However, its clinical application is restricted by the severe side effects stemming from poor tumor selectivity. In this study, MTO and cholesterol (CLS) were conjugated via a tumor-selective disulfide bond to obtain the MTO-SS-CLS prodrug. Interestingly, the MTO-SS-CLS could self-assemble into uniform nanoassemblies, and the addition of DSPE-PEG2K significantly improved its self-assembly behavior and stability. Moreover, compared with MTO solutions, the disulfide bond-bridged MTO-SS-CLS nanoassemblies exhibited heightened tumor selectivity and pharmacokinetic properties. In addition, the prodrug nanoassemblies improved the tolerated dose and safety of MTO without compromising its therapeutic effect. This research enriches the pharmaceutical research of MTO and paves the way for its extensive clinical application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.